Philippe Sauvage net worth and biography

Philippe Sauvage Biography and Net Worth

CFO of Nuvation Bio

Mr. Sauvage joined Nuvation Bio in 2024, bringing more than 20 years of experience building strategically aligned operations and finance teams in worldwide commercial settings.

He most recently served as Global Head of Operations and Access at Sanofi, where he led global strategic segments including commercial systems, competitive intelligence, multichannel strategy, and market access. Previously, Mr. Sauvage served as Chief Financial Officer, Sanofi-Genzyme and Sanofi North America where he led the financial operations for all US entities in a $14 billion region. Concurrently, he led the financial operations of Sanofi’s Global Specialty Care business through a period of rapid transformation that generated double-digit growth. Prior to this role, he served as CFO of Sanofi’s highly diversified, $5 billion JPAC Region and was the CFO for Japan, the organization’s second-largest country business. Prior to joining Sanofi, Mr. Sauvage was Chief Economic & Financial Officer with Assistance Publique Hôpitaux de Paris, the largest French public health institution and university hospital serving Paris and surrounding areas.

Mr. Sauvage is a member of the Board of Directors of the French American Chamber of Commerce, New England Chapter, the Dimock Health Center, and the Cair Group. In the past, he served as a Board Observer for DiCE Molecules.

Mr. Sauvage has a Research Masters in Macro-Economics from Panthéon-Sorbonne University in Paris. He also earned a Master of Science, Engineering from École Polytechnique, and completed an elite Civil Servant Education in Corps des Mines at Mines ParisTech.

What is Philippe Sauvage's net worth?: The estimated net worth of Philippe Sauvage is at least $70.15 thousand as of June 23rd, 2026. Mr. Sauvage owns 12,673 shares of Nuvation Bio stock worth more than $70,145 as of June 29th. This net worth approximation does not reflect any other investments that Mr. Sauvage may own. Learn More about Philippe Sauvage's net worth.
How do I contact Philippe Sauvage?: The corporate mailing address for Mr. Sauvage and other Nuvation Bio executives is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. Nuvation Bio can also be reached via phone at 332-208-6102 and via email at [email protected]. Learn More on Philippe Sauvage's contact information.
Has Philippe Sauvage been buying or selling shares of Nuvation Bio?: In the last ninety days, Philippe Sauvage has sold $286,484.68 in shares of Nuvation Bio stock. Most recently, Philippe Sauvage sold 47,668 shares of the business's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $6.01, for a transaction totalling $286,484.68. Following the completion of the sale, the chief financial officer now directly owns 12,673 shares of the company's stock, valued at $76,164.73. Learn More on Philippe Sauvage's trading history.
Who are Nuvation Bio's active insiders?: Nuvation Bio's insider roster includes Kim Blickenstaff (Director), Xiangmin Cui (Director), Jennifer Fox (CFO & Sec. ), Gary Hattersley (Chief Scientific Officer), David Hung (Founder), David Hung (CEO), Robert Mashal (Director), Oleg Nodelman (Director), Philippe Sauvage (CFO), and Kerry Wentworth (Chief Regulatory Officer). Learn More on Nuvation Bio's active insiders.
Are insiders buying or selling shares of Nuvation Bio?: During the last year, Nuvation Bio insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $118,250.00. During the last year, insiders at the sold shares 13 times. They sold a total of 842,418 shares worth more than $4,809,412.18. The most recent insider tranaction occured on June, 23rd when insider Stacy Markel sold 125,000 shares worth more than $753,750.00. Insiders at Nuvation Bio own 30.1% of the company. Learn More about insider trades at Nuvation Bio.
Information on this page was last updated on 6/23/2026.

Philippe Sauvage Insider Trading History at Nuvation Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/23/2026	Sell	47,668	$6.01	$286,484.68	12,673

Philippe Sauvage Buying and Selling Activity at Nuvation Bio

Nuvation Bio Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Today's Range

Now: $5.60

$5.39

$5.65

50 Day Range

MA: $4.94

$4.22

$6.52

2 Week Range

Now: $5.60

$1.87

$9.75

Volume

8,522,798 shs

Average Volume

5,294,578 shs

Market Capitalization

$1.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52